Mercury Laboratories (MERCURYLAB) | Financial Analysis & Statements
Mercury Laboratories Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
181.4M
Gross Profit
108.9M
60.02%
Operating Income
15.1M
8.34%
Net Income
9.7M
5.34%
EPS (Diluted)
₹8.06
Balance Sheet Metrics
Total Assets
743.2M
Total Liabilities
206.7M
Shareholders Equity
535.7M
Debt to Equity
0.39
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Mercury Laboratories Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 751.0M | 755.6M | 753.3M | 579.2M | 686.0M |
| Cost of Goods Sold | 289.2M | 305.4M | 306.1M | 237.6M | 313.8M |
| Gross Profit | 461.9M | 450.2M | 447.3M | 341.6M | 372.3M |
| Gross Margin % | 61.5% | 59.6% | 59.4% | 59.0% | 54.3% |
| Operating Expenses | |||||
| Research & Development | - | 245.0K | 85.0K | 241.0K | 26.0K |
| Selling, General & Administrative | 59.1M | 61.2M | 62.2M | 37.0M | 48.8M |
| Other Operating Expenses | 124.9M | 138.3M | 151.3M | 105.9M | 108.3M |
| Total Operating Expenses | 183.9M | 199.8M | 213.6M | 143.2M | 157.1M |
| Operating Income | 74.1M | 76.6M | 66.0M | 47.8M | 92.2M |
| Operating Margin % | 9.9% | 10.1% | 8.8% | 8.2% | 13.4% |
| Non-Operating Items | |||||
| Interest Income | 944.0K | 1.2M | 1.2M | 884.0K | 575.0K |
| Interest Expense | 2.2M | 646.0K | 570.0K | 1.7M | 2.5M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 46.6M | 69.2M | 74.4M | 50.3M | 79.1M |
| Income Tax | 15.2M | 12.7M | 18.7M | 14.7M | 25.7M |
| Effective Tax Rate % | 32.5% | 18.3% | 25.1% | 29.2% | 32.5% |
| Net Income | 31.4M | 56.5M | 55.8M | 35.6M | 53.4M |
| Net Margin % | 4.2% | 7.5% | 7.4% | 6.1% | 7.8% |
| Key Metrics | |||||
| EBITDA | 109.7M | 111.8M | 105.0M | 77.2M | 116.3M |
| EPS (Basic) | ₹26.21 | ₹47.12 | ₹46.49 | ₹29.68 | ₹44.48 |
| EPS (Diluted) | ₹26.21 | ₹47.12 | ₹46.49 | ₹29.68 | ₹44.48 |
| Basic Shares Outstanding | 1200000 | 1200000 | 1200000 | 1200000 | 1200000 |
| Diluted Shares Outstanding | 1200000 | 1200000 | 1200000 | 1200000 | 1200000 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Mercury Laboratories Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 3.3M | 32.9M | 37.1M | 41.1M | 30.3M |
| Short-term Investments | 13.0M | 48.0M | 31.5M | 21.2M | 11.5M |
| Accounts Receivable | 257.4M | 218.5M | 213.7M | 167.4M | 225.4M |
| Inventory | 72.1M | 62.1M | 69.0M | 67.8M | 51.6M |
| Other Current Assets | 47.2M | 33.4M | 55.6M | 42.5M | 47.5M |
| Total Current Assets | 401.6M | 398.4M | 394.6M | 352.2M | 378.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 85.4M | 76.5M | 73.7M | 70.6M | 70.9M |
| Goodwill | 263.0K | 254.0K | 408.0K | 562.0K | 838.0K |
| Intangible Assets | 263.0K | 254.0K | 408.0K | 562.0K | 838.0K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.9M | 2.7M | 14.7M | 13.9M | 12.1M |
| Total Non-Current Assets | 341.6M | 281.2M | 247.1M | 272.1M | 275.7M |
| Total Assets | 743.2M | 679.6M | 641.6M | 624.3M | 653.7M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 98.3M | 51.8M | 63.8M | 68.7M | 117.8M |
| Short-term Debt | 16.7M | 26.4M | 33.7M | 30.8M | 8.6M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.2M | 2.9M | 2.6M | 11.3M | 18.6M |
| Total Current Liabilities | 150.8M | 129.4M | 141.8M | 157.5M | 188.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 37.8M | 29.2M | 24.7M | 29.0M | 62.4M |
| Deferred Tax Liabilities | 14.3M | 12.6M | 18.9M | 22.3M | 21.3M |
| Other Non-Current Liabilities | -2.0K | -2.0K | -2.0K | 1.0K | -1.0K |
| Total Non-Current Liabilities | 55.9M | 41.8M | 43.6M | 63.8M | 96.4M |
| Total Liabilities | 206.7M | 171.2M | 185.3M | 221.2M | 284.8M |
| Equity | |||||
| Common Stock | 12.0M | 12.0M | 12.0M | 12.0M | 12.0M |
| Retained Earnings | 86.6M | 59.3M | 42.0M | 25.4M | 29.2M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 535.7M | 508.4M | 456.3M | 403.1M | 368.9M |
| Key Metrics | |||||
| Total Debt | 54.5M | 55.5M | 58.3M | 59.9M | 71.0M |
| Working Capital | 250.8M | 268.9M | 252.8M | 194.7M | 189.6M |
Balance Sheet Composition
Mercury Laboratories Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 46.6M | 69.2M | 74.4M | 50.3M | 79.1M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -64.7M | 5.6M | -62.0M | 38.5M | -43.3M |
| Operating Cash Flow | -12.6M | 78.6M | 16.1M | 93.3M | 42.2M |
| Investing Activities | |||||
| Capital Expenditures | -90.4M | -62.7M | -10.6M | -18.9M | -46.2M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | 0 | 0 | 0 |
| Investment Sales | - | - | 0 | 0 | 0 |
| Investing Cash Flow | -90.4M | -62.7M | -10.6M | -18.9M | -46.2M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -4.2M | -4.2M | -4.2M | -2.4M | -4.2M |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | -19.2M | -6.9M | -2.1M | -5.7M | -5.1M |
| Free Cash Flow | -50.4M | 19.5M | 14.0M | 32.7M | 35.9M |
| Net Change in Cash | -122.3M | 9.0M | 3.4M | 68.7M | -9.0M |
Cash Flow Trend
Mercury Laboratories Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
18.15
Price to Book
1.54
Price to Sales
1.12
PEG Ratio
-1.11
Profitability Ratios
Profit Margin
6.20%
Operating Margin
8.99%
Return on Equity
5.87%
Return on Assets
4.23%
Financial Health
Current Ratio
3.43
Debt to Equity
10.77
Beta
0.44
Per Share Data
EPS (TTM)
₹39.30
Book Value per Share
₹464.51
Revenue per Share
₹634.50
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| MERCURYLAB | 855.8M | 18.15 | 1.54 | 5.87% | 6.20% | 10.77 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





